MCL1 and non-small cell lung carcinoma: In addition, we have recently demonstrated that the CDK inhibitor dinaciclib effectively blocks MCL-1 to sensitize EGFR inhibitors in EGFR-mutant non-small cell lung cancer (NSCLC)14.